acquired
Stage
1
Investors
About
Y-mAbs Therapeutics develops and commercializes radioimmunotherapy and antibody-based oncology therapies; its marketed product DANYELZA (naxitamab) is indicated for relapsed or refractory high‑risk neuroblastoma. The company focuses on developing targeted biologic treatments for difficult-to-treat cancers.
Explore Y-mAbs Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.